Genertec Universal Medical Group Co Ltd
HKEX:2666
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (1.9), the stock would be worth HK$6.58 (12% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | HK$5.89 |
0%
|
| 3-Year Average | 1.9 | HK$6.58 |
+12%
|
| 5-Year Average | 1.8 | HK$6.06 |
+3%
|
| Industry Average | 4.5 | HK$15.58 |
+165%
|
| Country Average | 18.3 | HK$62.63 |
+963%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Genertec Universal Medical Group Co Ltd
HKEX:2666
|
11.2B HKD | 1.7 | 4.6 | |
| IN |
S
|
SPS Finquest Ltd
BSE:538402
|
2.6T INR | 12 169.2 | 877 228.1 | |
| TR |
D
|
Destek Finans Faktoring AS
IST:DSTKF.E
|
877.5B TRY | -193.8 | 233 | |
| IN |
|
Power Finance Corporation Ltd
NSE:PFC
|
1.5T INR | -2.3 | 6.1 | |
| IN |
|
Indian Railway Finance Corp Ltd
NSE:IRFC
|
1.4T INR | -13.8 | 19.8 | |
| JP |
|
Mitsubishi HC Capital Inc
TSE:8593
|
2T JPY | -9.7 | 11.1 | |
| IN |
|
REC Limited
NSE:RECLTD
|
984.8B INR | -6.6 | 5.7 | |
| JP |
|
Shinkin Central Bank
TSE:8421
|
1.7T JPY | 0 | 57.4 | |
| CA |
|
Element Fleet Management Corp
TSX:EFN
|
13.1B CAD | -87.1 | 46.8 | |
| TW |
|
Chailease Holding Company Ltd
TWSE:5871
|
207.9B TWD | 10.2 | 10.8 | |
| JP |
|
Tokyo Century Corp
TSE:8439
|
1T JPY | 7.9 | 7.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Genertec Universal Medical Group Co Ltd
Glance View
Genertec Universal Medical Group Co Ltd, a subsidiary of China General Technology Group, occupies a unique niche within the healthcare sector, primarily focusing on providing comprehensive financial services to hospitals across China. The company's narrative unfolds in the intricate world of healthcare finance, where it intertwines capital provision with healthcare infrastructure development. By offering medical equipment financing and leasing solutions, including managing operational leases and facilitating direct sales, Genertec Universal acts as a pivotal bridge connecting capital markets with hospitals in need of upgraded medical technology. This model ensures the company plays an integral role in the modernization of healthcare facilities across the nation, garnering growth as the demand for state-of-the-art medical infrastructure expands. The company extends its reach beyond the traditional lending sphere by incorporating a more diversified array of services, such as hospital management and consultancy, which allow it to deepen its involvement in the healthcare ecosystem. Through strategic partnerships and investment in hospital operations, Genertec Universal Medical Group not only provides financial backing but also advisory services aimed at enhancing operational efficiency and patient care standards. By leveraging its expertise and resources, the company secures a steady revenue stream while contributing to the improvement of healthcare services. This business model situates Genertec Universal as both a financial catalyst and a transformative agent within the healthcare industry, blending fiscal agility with a commitment to societal wellbeing.